A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects
- First Posted Date
- 2021-05-27
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 328
- Registration Number
- NCT04904913
- Locations
- 🇨🇳
Peking University people's hospital, Beijing, Beijing, China
A Study to Evaluate the Similarity in Pharmacokinetics and Safety of IBI310 and Ipilimumab（YERVOY）in Adult Healthy Chinese Male Volunteers
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 148
- Registration Number
- NCT04868760
- Locations
- 🇨🇳
Huashan Hospital Affiliated to Fudan University, Shanghai, China
IBI188 Combination Therapy in Solid Tumors
Phase 1
Terminated
- Conditions
- OsteosarcomaSolid TumorsLung Adenocarcinoma
- Interventions
- Drug: Cisplatin/Carboplatin
- First Posted Date
- 2021-04-27
- Last Posted Date
- 2022-10-04
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 9
- Registration Number
- NCT04861948
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
A Study of IBI302 in Patients With nAMD
Phase 2
Completed
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- First Posted Date
- 2021-03-29
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 231
- Registration Number
- NCT04820452
- Locations
- 🇨🇳
Innovent Biologics (Suzhou) Co,Ltd., Suzhou, Jiangsu, China
A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Hematologic Malignancy
- First Posted Date
- 2021-03-12
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 70
- Registration Number
- NCT04795128
- Locations
- 🇨🇳
The Second Affiliated Hospital Zhejiang University School of Medicine, Zhejiang, China
Clinical Study of IBI362 in Healthy Chinese Male Subjects
Phase 1
Completed
- Conditions
- Overweight/Obesity
- Interventions
- Drug: IBI362 lyophilized powderDrug: IBI362 liquid formulation
- First Posted Date
- 2021-02-26
- Last Posted Date
- 2021-07-08
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04773977
- Locations
- 🇨🇳
The Sceond Affiliated Hospital of Nanchang University, Nanchang, China
A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC
Phase 3
Recruiting
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2022-09-19
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 490
- Registration Number
- NCT04720716
- Locations
- 🇨🇳
Fudan Universtiy Zhongshan Hospital, Shanghai, Shanghai, China
A Study of IBI306 in Participants With Hypercholesterolemia
- First Posted Date
- 2021-01-14
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 306
- Registration Number
- NCT04709536
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, China
Study of the Efficacy and Safety of IBI319 in Patients With Advanced Malignant Tumors
- First Posted Date
- 2021-01-13
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 256
- Registration Number
- NCT04708210
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangdong, China
A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106)
Phase 3
Terminated
- Conditions
- Gastric Adenocarcinoma
- Interventions
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT04675983
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, China
© Copyright 2025. All Rights Reserved by MedPath